onalespib
Small moleculeexperimental
Clinical trial activity
13 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2008 (NCT00878423)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Intestinal Neoplasms · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Anaplastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Melanoma · Phase 1
- Mutation · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1/Phase 2
Mechanism of action
HSP90AB2P inhibitor
- Heat shock protein HSP90INHIBITOR
Heat shock protein HSP90 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O- Mol. weight
- 409.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1214827 ↗
Also known as
- (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone
- at13387
- at13387
- at13387
- at 13387
- at-13387
- ati-13387x
- ati-13387x
- onalespib
- onalespib
- onalespib
- onalespib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02898207 | Phase 1 | May 19, 2017 | Harvard University, National Cancer Institute (NCI) |
| NCT02503709 | Phase 1 | Apr 8, 2016 | Harvard University, National Cancer Institute (NCI) |
| NCT02572453 | Phase 2 | Apr 4, 2016 | Harvard University, National Cancer Institute (NCI) |
| NCT02627430 | Phase 1 | Mar 1, 2016 | Harvard University, National Cancer Institute (NCI) |
| NCT02535338 | Phase 1/Phase 2 (Phase 2) | Jan 21, 2016 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02474173 | Phase 1 | Jan 15, 2016 | National Cancer Institute (NCI), Ohio State University |
| NCT02381535 | Phase 1 | Sep 21, 2015 | National Cancer Institute (NCI), University of Toronto |
| NCT02097225 | Phase 1 | May 29, 2014 | Harvard University, National Cancer Institute (NCI) |
| NCT01712217 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2012 | Astex Pharmaceuticals, Inc., Institut Gustave Roussy |
| NCT01685268 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2012 | Astex Pharmaceuticals, Inc., Royal Marsden Hospital NHS Trust |
| NCT01294202 | Phase 2 | Mar 1, 2011 | Astex Pharmaceuticals, Inc., Harvard University |
| NCT01246102 | Phase 1 | Nov 1, 2010 | National Cancer Institute (NCI) |
| NCT00878423 | Phase 1 | May 1, 2008 | Astex Pharmaceuticals, Inc., Harvard University |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 9 | 9 | 2 | 2010 |
| Harvard University | Academic/Hospital | 7 | 0 | 2 | 2008 |
| Astex Pharmaceuticals, Inc. | For profit | 4 | 4 | 2 | 2008 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2015 |
8 organizations
Page 1 / 1